Gilead Sciences annual free cash flow per share
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Free Cash Flow Per Share Growth & History (GILD)
Gilead Sciences's free cash flow per share was $7.60 for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.60 | -$0.66 | −8.02% |
| 2024 | 2024-12-31 | $8.26 | $2.32 | +38.97% |
| 2023 | 2023-12-31 | $5.95 | -$0.70 | −10.56% |
| 2022 | 2022-12-31 | $6.65 | -$1.95 | −22.71% |
| 2021 | 2021-12-31 | $8.60 | $2.62 | +43.84% |
| 2020 | 2020-12-31 | $5.98 | -$0.57 | −8.69% |
| 2019 | 2019-12-31 | $6.55 | $0.79 | +13.73% |
| 2018 | 2018-12-31 | $5.76 | -$2.89 | −33.43% |
| 2017 | 2017-12-31 | $8.65 | -$3.52 | −28.92% |
| 2016 | 2016-12-31 | $12.17 | -$1.83 | −13.08% |
| 2015 | 2015-12-31 | $14.00 | $5.95 | +73.85% |
| 2014 | 2014-12-31 | $8.06 | $6.11 | +314.59% |
| 2013 | 2013-12-31 | $1.94 | $0.10 | +5.21% |
| 2012 | 2012-12-31 | $1.85 | -$0.42 | −18.39% |
| 2011 | 2011-12-31 | $2.26 | $0.64 | +39.77% |
| 2010 | 2010-12-31 | $1.62 | $0.04 | +2.78% |
| 2009 | 2009-12-31 | $1.58 | $0.47 | +43.01% |
| 2008 | 2008-12-31 | $1.10 | $0.25 | +28.71% |
| 2007 | 2007-12-31 | $0.86 | — | — |
Gilead Sciences quarterly free cash flow per share
Q3.08
Q1.09
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.76 | $2.18 | +377.57% |
| Q1 2026 | 2026-03-31 | $1.95 | $0.63 | +47.30% |
| Q4 2025 | 2025-12-31 | $2.51 | — | — |
| Q3 2025 | 2025-09-30 | $3.19 | -$0.16 | −4.66% |
| Q2 2025 | 2025-06-30 | $0.58 | -$0.38 | −39.65% |
| Q1 2025 | 2025-03-31 | $1.33 | -$0.37 | −21.74% |
| Q3 2024 | 2024-09-30 | $3.34 | $2.03 | +155.44% |
| Q2 2024 | 2024-06-30 | $0.96 | -$0.80 | −45.57% |
| Q1 2024 | 2024-03-31 | $1.70 | $0.39 | +29.40% |
| Q3 2023 | 2023-09-30 | $1.31 | -$0.85 | −39.31% |
| Q2 2023 | 2023-06-30 | $1.76 | $0.44 | +33.29% |
| Q1 2023 | 2023-03-31 | $1.31 | $0.04 | +3.21% |
| Q3 2022 | 2022-09-30 | $2.16 | -$0.32 | −13.03% |
| Q2 2022 | 2022-06-30 | $1.32 | -$0.43 | −24.55% |
| Q1 2022 · Mar 31 | 2022-03-31 | $1.27 | -$0.68 | −34.79% |
| Q3 2021 | 2021-09-30 | $2.48 | $0.81 | +48.52% |
| Q2 2021 | 2021-06-30 | $1.75 | -$0.18 | −9.33% |
| Q1 2021 | 2021-03-31 | $1.95 | $0.94 | +94.20% |
| Q3 2020 | 2020-09-30 | $1.67 | -$0.26 | −13.50% |
| Q2 2020 | 2020-06-30 | $1.93 | $0.23 | +13.67% |
| Q1 2020 | 2020-03-31 | $1.00 | -$0.05 | −4.55% |
| Q3 2019 | 2019-09-30 | $1.93 | $0.35 | +22.30% |
| Q2 2019 | 2019-06-30 | $1.70 | $0.72 | +72.77% |
| Q1 2019 | 2019-03-31 | $1.05 | -$0.52 | −33.31% |
| Q3 2018 | 2018-09-30 | $1.58 | -$0.39 | −19.66% |
| Q2 2018 | 2018-06-30 | $0.98 | -$1.62 | −62.24% |
| Q1 2018 | 2018-03-31 | $1.57 | -$0.57 | −26.63% |
| Q3 2017 | 2017-09-30 | $1.96 | -$1.21 | −38.11% |
| Q2 2017 | 2017-06-30 | $2.60 | -$0.98 | −27.30% |
| Q1 2017 | 2017-03-31 | $2.15 | -$0.71 | −24.92% |
| Q3 2016 | 2016-09-30 | $3.17 | $0.57 | +21.85% |
| Q2 2016 | 2016-06-30 | $3.58 | -$0.15 | −3.93% |
| Q1 2016 | 2016-03-31 | $2.86 | -$0.89 | −23.74% |
| Q3 2015 | 2015-09-30 | $2.60 | $0.02 | +0.88% |
| Q2 2015 | 2015-06-30 | $3.73 | $1.06 | +39.56% |
| Q1 2015 | 2015-03-31 | $3.75 | $2.83 | +310.30% |
| Q3 2014 | 2014-09-30 | $2.58 | $2.11 | +452.47% |
| Q2 2014 | 2014-06-30 | $2.67 | $2.08 | +349.29% |
| Q1 2014 | 2014-03-31 | $0.91 | $0.50 | +119.46% |
| Q3 2013 | 2013-09-30 | $0.47 | $0.02 | +4.28% |
| Q2 2013 | 2013-06-30 | $0.59 | -$0.23 | −28.19% |
| Q1 2013 | 2013-03-31 | $0.42 | $0.13 | +46.49% |
| Q3 2012 | 2012-09-30 | $0.45 | -$0.10 | −18.61% |
| Q2 2012 | 2012-06-30 | $0.83 | $0.24 | +41.76% |
| Q1 2012 | 2012-03-31 | $0.28 | -$0.22 | −43.85% |
| Q3 2011 | 2011-09-30 | $0.55 | $0.11 | +25.90% |
| Q2 2011 | 2011-06-30 | $0.58 | $0.20 | +50.79% |
| Q1 2011 | 2011-03-31 | $0.51 | $0.14 | +38.48% |
| Q3 2010 | 2010-09-30 | $0.44 | -$0.03 | −6.21% |
| Q2 2010 | 2010-06-30 | $0.39 | $0.05 | +16.51% |
| Q1 2010 | 2010-03-31 | $0.37 | $0.10 | +39.31% |
| Q3 2009 | 2009-09-30 | $0.47 | $0.20 | +76.28% |
| Q2 2009 | 2009-06-30 | $0.33 | — | — |
| Q1 2009 | 2009-03-31 | $0.26 | — | — |
| Q3 2008 | 2008-09-30 | $0.26 | — | — |
Gilead Sciences free cash flow per share trends
Over the last five fiscal years, Gilead Sciences's free cash flow per share increased from $5.98 to $7.60, a change of $1.62. The latest reported quarter, Q2 2026, shows $2.76.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
